Stanley Laman Group Ltd. Invests $9.05 Million in Shockwave Medical, Inc. (NASDAQ:SWAV)

Stanley Laman Group Ltd. bought a new position in shares of Shockwave Medical, Inc. (NASDAQ:SWAV) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 47,471 shares of the company’s stock, valued at approximately $9,046,000. Shockwave Medical makes up approximately 1.4% of Stanley Laman Group Ltd.’s investment portfolio, making the stock its 9th largest position.

A number of other institutional investors and hedge funds have also modified their holdings of SWAV. Lindbrook Capital LLC boosted its holdings in Shockwave Medical by 64.8% in the 3rd quarter. Lindbrook Capital LLC now owns 150 shares of the company’s stock valued at $30,000 after purchasing an additional 59 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Shockwave Medical by 297.4% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 155 shares of the company’s stock valued at $31,000 after purchasing an additional 116 shares during the last quarter. Asset Management One Co. Ltd. acquired a new position in Shockwave Medical in the 4th quarter valued at about $34,000. Operose Advisors LLC acquired a new position in Shockwave Medical in the 3rd quarter valued at about $49,000. Finally, Venturi Wealth Management LLC acquired a new position in Shockwave Medical in the 3rd quarter valued at about $82,000. Hedge funds and other institutional investors own 95.35% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on SWAV shares. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $335.00 price objective (up from $270.00) on shares of Shockwave Medical in a report on Monday, April 8th. Wolfe Research restated a “peer perform” rating on shares of Shockwave Medical in a report on Friday, April 5th. Leerink Partnrs lowered shares of Shockwave Medical from an “outperform” rating to a “market perform” rating in a report on Friday, April 5th. TheStreet upgraded shares of Shockwave Medical from a “c+” rating to a “b” rating in a report on Thursday, February 15th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Shockwave Medical in a research note on Friday, April 5th. Ten equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, Shockwave Medical currently has an average rating of “Hold” and an average price target of $309.11.

Shockwave Medical Stock Up 0.0 %

Shares of NASDAQ:SWAV traded up $0.12 during trading hours on Thursday, reaching $328.99. The stock had a trading volume of 597,448 shares, compared to its average volume of 959,437. Shockwave Medical, Inc. has a 1 year low of $157.00 and a 1 year high of $331.58. The firm’s 50 day moving average is $293.53 and its 200-day moving average is $232.36. The company has a debt-to-equity ratio of 1.09, a quick ratio of 10.73 and a current ratio of 11.76. The stock has a market capitalization of $12.30 billion, a price-to-earnings ratio of 85.01, a P/E/G ratio of 2.44 and a beta of 0.92.

Shockwave Medical (NASDAQ:SWAV) last announced its quarterly earnings data on Thursday, February 15th. The company reported $1.16 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.24. Shockwave Medical had a net margin of 20.17% and a return on equity of 23.97%. The company had revenue of $202.98 million for the quarter, compared to the consensus estimate of $199.43 million. During the same period in the prior year, the firm posted $3.71 EPS. The company’s quarterly revenue was up 41.0% compared to the same quarter last year. Research analysts predict that Shockwave Medical, Inc. will post 4.94 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Isaac Zacharias sold 4,000 shares of the company’s stock in a transaction on Friday, January 26th. The shares were sold at an average price of $224.69, for a total value of $898,760.00. Following the completion of the transaction, the insider now owns 63,920 shares in the company, valued at approximately $14,362,184.80. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, CFO Dan Puckett sold 3,406 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $229.76, for a total transaction of $782,562.56. Following the completion of the sale, the chief financial officer now owns 27,732 shares in the company, valued at approximately $6,371,704.32. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Isaac Zacharias sold 4,000 shares of the stock in a transaction on Friday, January 26th. The stock was sold at an average price of $224.69, for a total transaction of $898,760.00. Following the sale, the insider now owns 63,920 shares of the company’s stock, valued at approximately $14,362,184.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 93,813 shares of company stock worth $23,762,679. Corporate insiders own 3.40% of the company’s stock.

About Shockwave Medical

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.